Please assess the completion status of the following clinical trial:

Trial Title: Safety, Tolerability, Efficacy and Optimal Dose Finding Study of BAF312 in Patients With Relapsing-remitting Multiple Sclerosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Key inclusion Criteria:~* Diagnosis of Multiple Sclerosis (MS) as defined by revised McDonald criteria.~* A relapsing-remitting course of disease with at least 1 documented relapse during the previous year, or 2 documented relapses during the previous 2 years, or a positive gadolinium (Gd)-enhanced MRI scan at screening (in case the first MRI scan obtained at screening is negative, a second scan may be obtained 1 month later.)~* An Expanded Disability Status Scale (EDSS) score of 0-5.0 inclusive at randomization.~* Neurologically stable with no evidence of relapse or corticosteroid treatment within 30 days prior to randomization.~* Patients who decline initiation or continuation of treatment with available disease modifying drugs for MS, for whatever reason, after having been informed about their respective benefits and possible adverse events by the investigator.~Key exclusion Criteria:~* A manifestation of another type of MS than RRMS~* History of chronic disease of the immune system other than MS~* Malignancies, diabetes, significant cardiovascular, pulmonary and hepatic diseases and conditions~* Active infections

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- BAF312 10mg (period 1) (Type: EXPERIMENTAL): None
- BAF312 2 mg (period 1) (Type: EXPERIMENTAL): None
- BAF312 0.5 mg (period 1) (Type: EXPERIMENTAL): None
- BAF312 dose between 0.1 to 8 mg period 2 (Type: EXPERIMENTAL): None
- BAF312 dose between 0.1 - 8 mg period 2 (Type: EXPERIMENTAL): None
- Placebo (period 1, 2) (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).